Biography

Dr. Eric Wombwell is a board-certified infectious diseases pharmacist and clinical professor for the Division of Pharmacy Practice and Administration at the University of Missouri-Kansas City School of Pharmacy, where he is responsible for developing clinical and educational initiatives that promote optimal antimicrobial use.  Dr. Wombwell completed his Pharm.D. degree at the University of Missouri-Kansas City, followed by an ASHP accredited pharmacy practice residency at the Kansas City VA Medical Center. He has over 15 years of infectious diseases clinical practice experience, maintaining an appointment at Centerpoint Medical Center where he provides infectious diseases and antimicrobial stewardship support and precepts the pharmacy residency infectious diseases rotation. Dr. Wombwell has published extensively in peer-reviewed journals on pharmacy and infectious diseases-related topics. His research, particularly on Clostridioides difficile infection prevention measures, has been widely recognized, leading to citations in UpToDate and international treatment guidelines. A dynamic and engaging teacher, Dr. Wombwell has delivered over 100 continuing education presentations to various health-professional audiences both locally and nationally. His dedication to teaching excellence has been acknowledged through numerous recognitions, including the University of Missouri-Kansas City Provost’s Award for Excellence in Teaching.

Research Interests
Healthcare Acquired Infections
Probiotics

Recent Awards (selected)
Rho Chi Society – ΑΩ Chapter Outstanding Teacher of the Year; 2022
Phi Lambda Sigma – βη Chapter Alumnus of the Year; 2021
UMKC School of Pharmacy Class of 2020 Teacher of the Year; 2019
UMKC School of Dentistry D3 Class Lecturer of the Year; 2018
Missouri Pharmacy Association UMKC Faculty of the Year; 2016
UMKC Provost’s Award for Excellence in Teaching; 2014

Recent Publications

• Wombwell E, Rosa A. Comparison of Cefazolin and Ceftriaxone Enterobacterales Susceptibilities for Inpatient Treatment of Urinary Tract Infections and Risk of Hospital-Onset Clostridioides difficile Infection. Clin Ther. 2024 Jun;46(6):451-454. doi: 10.1016/j.clinthera.2024.02.011. Epub 2024 Mar 28.
• Bowers BL, Sperry M, Englin EF, Wombwell E. Evidence-Based Medicine and Pharmacotherapy Content Alignment. Am J Pharm Educ. 2023;87(10):100554. doi: 10.1016/j.ajpe.2023.100554. Epub 2023 Jun 28.
• Wombwell E. Saccharomyces boulardii Prophylaxis for Targeted Antibiotics and Infectious Indications to Reduce Healthcare Facility-Onset Clostridioides difficile Infection. Microbes Infect. 2023;25(3):105041. doi: 10.1016/j.micinf.2022.105041. Epub 2022 Sep 1.
  Wombwell E. Saccharomyces boulardii Administration and Fecal Microbiota Transplant Response in Recipients Treated for Recurrent Clostridioides difficile Infection. Infect Dis Diag Treat. 2022;6:193. doi: 10.29011/2577- 1515.100193
• Wombwell E, Bransteitter B, Gillen LR. Incidence of Saccharomyces cerevisiae Fungemia in Hospitalized Patients Administered Saccharomyces boulardii Probiotic. Mycoses. 2021;64(12):1521-1526. doi: 10.1111/myc.13375.
• Wombwell E, Patterson ME, Gillen LR, Bransteitter B. The effect of Saccharomyces boulardii primary prevention on risk of Hospital Onset Clostridioides difficile infection in hospitalized patients administered antibiotics frequently associated with Clostridioides difficile infection. Clin Infect Dis. 2021;73(9):e2512-e2518. doi: 10.1093/cid/ciaa808